

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Kaisa Health Group Holdings Limited
佳兆業健康集團控股有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 876)

PROFIT WARNING

This announcement is made by Kaisa Health Group Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of the Company hereby informs the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on a preliminary assessment on the unaudited management accounts of the Group for the year ended 31 December 2019 and information currently available to the Board, the Board expects the Group to record a loss attributable to the owners of the Company in the range of HK\$340 million to HK\$360 million for the year ended 31 December 2019 as compared to the loss attributable to the owners of the Company in the amount of approximately HK\$22 million for the year ended 31 December 2018.

The significant loss was mainly due to a combination of factors as follows:—

- (i) Although the Group recorded a 4% overall increase in terms of income for the year ended 31 December 2019 as compared with last year, the overall result in dental prosthetics business was lower than last year. This was mainly because:
 - a. US customers have adopted a conservative procurement attitude due to their rising concerns about the current status of trade conflicts between China and the United States. As a result of which, the Group offered a certain extent of price discount in order to secure more export orders;

- b. the Group has stepped up its investment in digitized equipment and thus depreciation of the newly invested equipment increased; and
 - c. the demand of the market for skilled labours was keen and hence drove up the labour cost.
- (ii) Merger and acquisition-related legal and professional fees as well as the introduction of medical professionals led to an increase in administrative expenses for the year under review.
- (iii) The Group increased its commitment to relevant research and development, which led to an increase in research and development expenses for the year under review.
- (iv) The full impairment of goodwill of approximately HK\$331 million and intangible assets of approximately HK\$27 million which reflect the significant devaluation of the dental prosthetics business acquired in 2015.

The Company is still in the process of finalizing the annual results of the Group for the year ended 31 December 2019. The information contained in this announcement is only based on the unaudited management accounts of the Group and information currently available to the Group, which is subject to finalization and necessary adjustments and has not been confirmed, audited or reviewed by the auditors of the Company. Details of the financial results of the Group will be disclosed in the Group's annual results announcement for the year which will be published in due course pursuant to the requirements of the Listing Rules. Shareholders and potential investors are advised to read the financial results announcement carefully when it is published.

Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Kaisa Health Group Holdings Limited
Luo Jun
Chief Executive Officer

Hong Kong, 17 March 2020

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Kwok Ying Shing (Chairman), Mr. Luo Jun (Co-Vice Chairman), Mr. Wu Tianyu (Co-Vice Chairman) and Mr. Xu Hao, and four independent non-executive Directors, namely Dr. Liu Yanwen, Mr. Lau Shui Fung, Mr. Fok Hei Yu and Dr. Lyu Aiping.